BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Canadian Rare Disease Network - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Canadian Rare Disease Network
X-ORIGINAL-URL:https://canadianrdn.ca
X-WR-CALDESC:Events for Canadian Rare Disease Network
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Edmonton
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20270314T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20271107T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Lisbon
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:WEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:WET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:WEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:WET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:WEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:WET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Edmonton:20260203T170000
DTEND;TZID=America/Edmonton:20260203T183000
DTSTAMP:20260520T054423
CREATED:20260105T200023Z
LAST-MODIFIED:20260105T200023Z
UID:9585-1770138000-1770143400@canadianrdn.ca
SUMMARY:RealiseD Webinar 3: Single arm\, RCT or something in between – how to enrich clinical trial design and analysis in rare diseases
DESCRIPTION:Single-arm trials remain a cornerstone of rare disease research\, but their limitations and complexities cannot be ignored. In the third webinar\, experts Yulia Dyachkova (Merck Healthcare)\, Jenny Devenport (Roche)\, Cornelia Dunger-Baldauf (Novartis) abd Guillaume Canaud will lead a deep dive into the evolving role of SATs in drug development. The discussion will cover regulatory and HTA perspectives\, review case studies of success and failure\, and explore advanced statistical methods designed to optimise trial design. This session is not just about understanding the current landscape—it is about shaping the future of evidence generation for rare and ultra-rare diseases.
URL:https://canadianrdn.ca/event/realised-webinar-3-single-arm-rct-or-something-in-between-how-to-enrich-clinical-trial-design-and-analysis-in-rare-diseases/
CATEGORIES:Clinical Trials,Healthcare,International,Patient Focused,Policy,Research Focused,Virtual,Webinars
ATTACH;FMTTYPE=image/jpeg:https://canadianrdn.ca/wp-content/uploads/2026/01/RealiseD-Visuals-Webinars-2026-800x450-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Edmonton:20260204T150000
DTEND;TZID=America/Edmonton:20260204T160000
DTSTAMP:20260520T054423
CREATED:20260126T210046Z
LAST-MODIFIED:20260126T210046Z
UID:9647-1770217200-1770220800@canadianrdn.ca
SUMMARY:RareKids-CAN- From Evidence to Access: Advancing Pediatric Rare Disease Drug Availability in Canada
DESCRIPTION:Join RareKids-CAN for an in-depth discussion on the evolving role of health technology assessment and reimbursement policy in improving access to pediatric rare disease care.
URL:https://canadianrdn.ca/event/rarekids-can-from-evidence-to-access-advancing-pediatric-rare-disease-drug-availability-in-canada/
CATEGORIES:Clinical Trials,Industry,National,Patient Focused,Research Focused,Virtual,Webinars
ATTACH;FMTTYPE=image/jpeg:https://canadianrdn.ca/wp-content/uploads/2026/01/1768928212783.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Lisbon:20260210T080000
DTEND;TZID=Europe/Lisbon:20260212T170000
DTSTAMP:20260520T054423
CREATED:20250812T193701Z
LAST-MODIFIED:20250812T193701Z
UID:8705-1770710400-1770915600@canadianrdn.ca
SUMMARY:8th TREAT-NMD® International Conference – Lisbon\, 2026
DESCRIPTION:Join TREAT-NMD at this vital\, in-person gathering where patients\, clinicians\, researchers\, industry\, and regulators come together to tackle the biggest challenges in neuromuscular treatment development\, diagnosis and care. Topics will include; disrupted clinical trial delivery\, regulatory uncertainty\, global access inequalities and shrinking public funding\, they’ll tackle these themes with a holistic\, solutions-driven approach and a patient centric and global focus.
URL:https://canadianrdn.ca/event/8th-treat-nmd-international-conference-lisbon-2026/
CATEGORIES:Caregiver,Clinical Trials,Conferences,Healthcare,In Person,International,Patient Focused,Policy,Research Focused
ATTACH;FMTTYPE=image/jpeg:https://canadianrdn.ca/wp-content/uploads/2025/08/town-5621642_1280-702x526-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Edmonton:20260210T170000
DTEND;TZID=America/Edmonton:20260210T183000
DTSTAMP:20260520T054423
CREATED:20260105T200202Z
LAST-MODIFIED:20260105T200202Z
UID:9588-1770742800-1770748200@canadianrdn.ca
SUMMARY:RealiseD Webinar 4: Enhancing patient-centricity in Rare Disease Clinical Trials
DESCRIPTION:The final webinar focuses on what truly matters: the patient. Rare disease trials often struggle to capture outcomes that reflect patient priorities but RealiseD is working to change that. Rudradev Sengupta\, Senior Trial Design Lead at One2Treat\, will present an approach that embeds patient voices into every stage of trial design and analysis. By using hierarchical endpoints and net treatment benefit\, this framework balances benefits and risks in alignment with patient preferences\, enabling transparent discussions among stakeholders and ensuring that success is defined by what matters most to patients. This is a vital conversation for anyone committed to making clinical research more humane and impactful.
URL:https://canadianrdn.ca/event/realised-webinar-4-enhancing-patient-centricity-in-rare-disease-clinical-trials/
CATEGORIES:Caregiver,Clinical Trials,Healthcare,International,Patient Focused,Policy,Research Focused,Virtual,Webinars
ATTACH;FMTTYPE=image/png:https://canadianrdn.ca/wp-content/uploads/2026/01/Coming-Soon.-5-800x450-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Edmonton:20260219T130000
DTEND;TZID=America/Edmonton:20260219T143000
DTSTAMP:20260520T054423
CREATED:20260212T210210Z
LAST-MODIFIED:20260212T210210Z
UID:9794-1771506000-1771511400@canadianrdn.ca
SUMMARY:Canada's Drug Agency: How Global Policy Changes Are Reshaping HTA for Rare Diseases
DESCRIPTION:HTAi’s Rare Disease Interest Group will celebrate 2026 Rare Disease Day with a conversation on how global policy changes are reshaping HTA processes for rare disease technologies. The webinar aims to update the global HTA community on recent advances in rare disease policy\, particularly following the adoption of the World Health Assembly (WHA) Resolution on Rare Diseases\, and to explore its implications for HTA systems globally. The multi-stakeholder expert panel will discuss how global policy commitments can translate into meaningful regional\, national\, and local action within HTA. This event is the inaugural webinar in a year-long webinar series\, catalyzing discussions on how legislative changes in health systems are reshaping HTA for rare diseases through regional real-world case studies and examples.
URL:https://canadianrdn.ca/event/canadas-drug-agency-how-global-policy-changes-are-reshaping-hta-for-rare-diseases/
CATEGORIES:Clinical Trials,Healthcare,Industry,National,Policy,Research Focused,Virtual,Webinars
ATTACH;FMTTYPE=image/png:https://canadianrdn.ca/wp-content/uploads/2026/02/CDA-HTI.png
END:VEVENT
END:VCALENDAR